{"id":448025,"date":"2025-05-06T14:06:44","date_gmt":"2025-05-06T14:06:44","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?p=448025"},"modified":"2025-05-13T10:18:00","modified_gmt":"2025-05-13T10:18:00","slug":"a-closer-look-at-four-of-this-years-drugs-to-watch","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/a-closer-look-at-four-of-this-years-drugs-to-watch\/","title":{"rendered":"A closer look at four of this year\u2019s Drugs to Watch"},"content":{"rendered":"<p>Sanofi\u2019s small interfering RNA hemophilia drug QFITLIA (fitusiran) recently became the latest of our 2025 Drugs to Watch <a href=\"https:\/\/www.bioworld.com\/articles\/718791-sanofi-adds-to-hemophilia-arsenal-with-fda-nod-for-qfitlia\" target=\"_blank\" rel=\"noopener\">to secure FDA approval<\/a>.<\/p>\n<p>The drug, approved March 28, is a first-in-class antithrombin-lowering therapy for use as a prophylactic treatment to prevent or reduce bleeding episodes in people with hemophilia A or B, with or without inhibitors. Developed using Alnylam Pharmaceutical Inc\u2019s ESC-GalNAc conjugate technology, the treatment\u2019s once-monthly or every-other-monthly subcutaneous infusions promise to lower treatment burdens for patients and enhance compliance while also offering an alternative for the 20-30% of patients treated with replacement therapies who develop inhibitors at some point.<\/p>\n<p>Mike Ward, Global Head of Thought Leadership at Clarivate, recently spoke to four analysts who worked on the report about some of their other 2025 picks. Among them:<\/p>\n<ul>\n<li><strong>Cobenfy<\/strong> \u2013 Bristol Myers Squibb\u2019s innovative schizophrenia drug, the first novel treatment for the disease in decades, launched late last year, recording $10 million in Q4 sales but forecast to be a blockbuster by 2030.<\/li>\n<\/ul>\n<p>\u201cCobenfy could help address the need for more effective treatments for both the positive and as well as negative symptoms,\u201d said Prakhar Saxena, an analyst on the CNS team at Clarivate. \u201cIt has an improved side effect profile &#8212; for example, a lack of extrapyramidal symptoms &#8212; and its novel mechanism of action could benefit schizophrenia patients.\u201d<\/p>\n<ul>\n<li><strong>Zanzalintinib<\/strong> \u2013 a third generation multitargeted tyrosine kinase inhibitor (TKI) developed by Exelixis, zanzalintinib is in testing both as a standalone and in combination with other treatments for solid tumors, notably non-clear cell renal cell carcinoma, where there is tremendous unmet need.<br \/>\n\u201cZanzalintinib could become the first therapy specifically approved for patients with the non-clear cell histology of RCC\u201d said Catherine Willoughby, Ph.D., an oncology analyst at Clarivate. Furthermore, the treatment \u201chas an improved pharmacokinetic profile,\u201d and \u201chas shown a favorable safety profile, with fewer adverse events compared with other TKIs, potentially making it more tolerable for long term use.\u201d<\/li>\n<li><strong>CagriSema<\/strong> \u2013 Novo Nordisk\u2019s next generation GLP-1 combination therapy for weight loss and type 2 diabetes, pairs semaglutide with cagrilintide, a long-acting amylin analogue. In March, the company reported findings from the REDEFINE 2 trial showing an average weight loss of 15.7% after 68 weeks, disappointing investors, who were looking for the drug to meet company projections of a 25% loss. The earlier phase 3 REDEFINE 1 trial found a 22.7% average weight loss for the same period in patients with obesity, with 40.5% achieving upwards of 25% &#8212; still short of investor expectations.<\/li>\n<\/ul>\n<p>\u201cThe results fell short of the 25% weight loss target expected by both Novo and investors but are superior to those achieved by the individual components of CagriSema,\u201d said Carles Recasens-Alvarez, Ph.D., a healthcare and data research analyst at Clarivate who studies the cardiovascular, renal, metabolic and hematology space.<\/p>\n<ul>\n<li><strong>mRESVIA<\/strong> \u2013 Moderna\u2019s mRNA vaccine for respiratory syncytial virus (RSV), which won FDA approval for use in adults 60 and up last May, is the third RSV vaccine to market but the first based on mRNA technology.<\/li>\n<\/ul>\n<p>\u201cThe mRNA technology allows for rapid design and production of the vaccine as well as providing potential for quick adaptation to new RSV strains as needed,\u201d said Sukhvinder Singh, Lead Healthcare Research and Data Analyst at Clarivate.<\/p>\n<p><a href=\"https:\/\/clarivate.com\/life-sciences-healthcare\/webinars\/drugs-to-watch-2025-four-treatment-paradigm-game-changers\/\">Watch the full webinar<\/a> for in-depth analysis of these four Drugs to Watch.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clarivate analysts offer insights into what made four of this year&#8217;s Drugs to Watch stand out.<\/p>\n","protected":false},"author":45,"featured_media":310081,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rank_math_lock_modified_date":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[19],"tags":[333,159,32],"class_list":["post-448025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","tag-pharma","tag-portfolio-strategy","tag-research-and-development","clarivate-content-type-blog","clarivate-product-biopharma"],"acf":[],"lang":"en","translations":{"en":448025},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/448025"}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=448025"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/448025\/revisions"}],"predecessor-version":[{"id":449418,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/448025\/revisions\/449418"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/310081"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=448025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=448025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=448025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}